Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Insulet ( (PODD) ) is now available.
On June 6, 2025, Insulet Corporation amended its Credit Agreement to refinance $481.25 million in term loans, reducing the interest rate margin and maintaining similar terms to the previous loans. Additionally, Insulet issued a redemption notice on June 9, 2025, for its outstanding Convertible Senior Notes due 2026, with plans to redeem them by August 20, 2025, potentially impacting stock transactions as hedge positions are unwound.
The most recent analyst rating on (PODD) stock is a Buy with a $380.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.
Spark’s Take on PODD Stock
According to Spark, TipRanks’ AI Analyst, PODD is a Outperform.
Insulet Corporation demonstrates strong financial performance and growth potential, supported by robust revenue and margin improvements. While technical and valuation indicators suggest caution, strategic leadership changes and positive earnings guidance bolster confidence in future growth. The stock is well-positioned in its industry but requires careful monitoring of valuation metrics.
To see Spark’s full report on PODD stock, click here.
More about Insulet
Insulet Corporation operates in the medical device industry, primarily focusing on the development and manufacturing of insulin management systems. The company is known for its innovative products aimed at improving the lives of people with diabetes.
Average Trading Volume: 882,181
Technical Sentiment Signal: Buy
Current Market Cap: $21.94B
See more insights into PODD stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue